Peter Attia
π€ SpeakerAppearances Over Time
Podcast Appearances
Creatine is ubiquitous.
There's no IP around it.
I want to give people some advice on how to go buy creatine because if you go to Amazon, it's like, which one do I buy?
But who's sort of taken the mantle on trying to understand this?
Because it is an important question.
And if you've got something that's insanely cheap, completely safe, has other benefits in the body anyway...
And all we're really trying to figure out is, hey, should we all just be doubling our dose from 5 to 10?
It'd be great to quantify the effect size and stratify patients that we need to be reaching out to.
Because again, not everybody listening to us is doing this anyway.
And it's just one more thing to ask somebody to do, which comes at a cost.
There's a psychic cost to just asking people to do more stuff.
And it's one more thing you got to do.
Again, this is like low hanging fruit in the world of biomedical research.
This has got like Dom D'Agostino's name written all over it.
We got to talk Dom into doing this.
I'm just going to be skeptical.
I still think that the name of the game is prevention, where I'm most interested.
And of course, that's the hardest thing to study.
But when we think about the energy crisis that is happening in a brain with Alzheimer's disease, and while I think you and I would agree there are probably many paths towards AD, there are inflammatory paths, there are lipid-mediated and vascular paths, and then there are sort of these more metabolic paths.
But when you take that individual who is most susceptible to the metabolic path towards dementia and 10 years earlier or 20 years earlier, you're giving them a substrate that is augmenting ATP creation.